Hillhouse Capital, a private equity firm, led a $310m Series C round in Everest Medicines, a biopharmaceutical startup. The investment round saw the participation from Janchor Partners, RA Capital Management, Janus Henderson Investors, Rock Springs Capital, Octagon Investments, Jiashan SDIC, and CBC Group. Proceeds from the financing will be used to advance clinical development of Everest Medicines’ robust pipeline of novel therapeutic candidates and build out a strong commercial infrastructure to support the next phase of growth. "We are proud of what Everest has achieved in such a short period since its inception in late 2017. The strong network of investors validates Everest Medicines’ early achievements, as well as their confidence in Everest’s potential to grow into a leading innovative drug platform company in the region," Wei Fu, Everest Medicines Wei Fu.